#### Check for updates

#### OPEN ACCESS

EDITED BY Somasundaram Arumugam, National Institute of Pharmaceutical Education and Research, Kolkata, India

REVIEWED BY Jong Hoon Ryu, Kyung Hee University, South Korea Anurag Varshney, Patanjali Research Foundation, India

\*CORRESPONDENCE Yoshihisa Kitamura, kitamu-y@shujitsu.ac.jp

SPECIALTY SECTION This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 05 March 2022 ACCEPTED 29 June 2022 PUBLISHED 12 August 2022

#### CITATION

Ushio S, Wada Y, Nakamura M, Matsumoto D, Hoshika K, Shiromizu S, Iwata N, Esumi S, Kajizono M, Kitamura Y and Sendo T (2022), Anxiolytic-like effects of hochuekkito in lipopolysaccharide-treated mice involve interleukin-6 inhibition. *Front. Pharmacol.* 13:890048. doi: 10.3389/fphar.2022.890048

#### COPYRIGHT

© 2022 Ushio, Wada, Nakamura, Matsumoto, Hoshika, Shiromizu, Iwata, Esumi, Kajizono, Kitamura and Sendo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Anxiolytic-like effects of hochuekkito in lipopolysaccharide-treated mice involve interleukin-6 inhibition

Soichiro Ushio<sup>1</sup>, Yudai Wada<sup>2</sup>, Mizuki Nakamura<sup>2</sup>, Daiki Matsumoto<sup>2</sup>, Kota Hoshika<sup>2</sup>, Shoya Shiromizu<sup>1</sup>, Naohiro Iwata<sup>1</sup>, Satoru Esumi<sup>1</sup>, Makoto Kajizono<sup>1</sup>, Yoshihisa Kitamura<sup>1,3</sup>\* and Toshiaki Sendo<sup>1</sup>

<sup>1</sup>Department of Pharmacy, Okayama University Hospital, Okayama, Japan, <sup>2</sup>Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, <sup>3</sup>Department of Pharmacotherapy, School of Pharmacy, Shujitsu University, Okayama, Japan

Hochuekkito (HET) is a Kampo medicine used to treat postoperative and postillness general malaise and decreased motivation. HET is known to regulate immunity and modulate inflammation. However, the precise mechanism and effects of HET on inflammation-induced central nervous system disorders remain unclear. This study aimed to assess the effect of HET on inflammation-induced anxiety-like behavior and the mechanism underlying anxiety-like behavior induced by lipopolysaccharide (LPS). Institute of Cancer Research mice were treated with LPS (300  $\mu$ g/kg, intraperitoneally), a bacterial endotoxin, to induce systemic inflammation. The mice were administered HET (1.0 g/kg, orally) once a day for 2 weeks before LPS treatment. The light-dark box test and the hole-board test were performed 24 h after the LPS injection to evaluate the effects of HET on anxiety-like behaviors. Serum samples were obtained at 2, 5, and 24 h after LPS injection, and interleukin-6 (IL-6) levels in serum were measured. Human and mouse macrophage cells (THP-1 and RAW264.7 cells, respectively) were used to investigate the effect of HET on LPS-induced IL-6 secretion. The repeated administration of HET prevented anxiety-like behavior and decreased serum IL-6 levels in LPS-treated mice. HET significantly suppressed LPS-induced IL-6 secretion in RAW264.7 and THP-1 cells. Similarly, glycyrrhizin, one of the chemical constituents of HET, suppressed LPS-induced anxiety-like behaviors. Our study revealed that HET ameliorated LPS-induced anxiety-like behavior and inhibited IL-6 release in vivo and in vitro. Therefore, we postulate that HET may be useful against inflammation-induced anxiety-like behavior.

**Abbreviations:** HET, Hochuekkito; LPS, lipopolysaccharide; IL-6, interleukin-6; TNF- $\alpha$ , tumor necrosis factor-alpha; IFN- $\gamma$ , interferon-gamma; IL-1 $\beta$ , interleukin-1 beta; JP, Japanese Pharmacopoeia; DMSO, dimethyl sulfoxide; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; NF- $\kappa$ B, nuclear factor-kappa B; MAPK, mitogen-activated protein kinase; GABA<sub>A</sub>,  $\gamma$ -aminobutyrate<sub>A</sub>; HMGB-1, high mobility group box 1; N.D, not detected.

KEYWORDS

anxiolytic, inflammation, immunomodulation, macrophages, Kampo medicine

## Introduction

Inflammation is the body's initial response to infection and tissue injury and has been shown to play an important role in the development of neurodegenerative diseases and psychiatric disorders, such as anxiety, bipolar disorder, schizophrenia, and depression (Berk et al., 2011; Leonard and Maes 2012; Yan et al., 2014; Khandaker et al., 2015; Månsson et al., 2022). The serum levels of pro-inflammatory cytokines, including interleukin-6 (IL-6), were higher in depressed patients with schizophrenia, bipolar disorder, and major depressive disorder (Dowlati et al., 2010; Goldsmith et al., 2016). In animal models, inflammatory conditions caused by the peripheral administration of lipopolysaccharide (LPS), which causes systemic inflammation through increased production of interferon-gamma (IFN-y), IL-6, and interleukin-1 beta (IL-1β), have been shown to lead to both depressive-like and anxiety-like behaviors (Godbout et al., 2005; Huang et al., 2008; Jangra et al., 2014). Our previous study revealed that the systemic administration of LPS increased serum IL-6 levels and hippocampal mRNA levels of IL-6 and tumor necrosis factor-alpha (TNF-a) (Kitamura et al., 2019). Furthermore, the reduction of blood cytokine levels has been suggested as a novel therapy for inflammation-induced psychotic disorders (Zhang et al., 2017).

The light-dark test and the hole-board test is an anxiogenic challenge for measuring the response of an animal model to an unfamiliar environment and has been used to examine the effects of benzodiazepine anxiolytics, such as diazepam, on their emotional behavior (Takeda et al., 1998; Bourin and Hascoët 2003). The typical benzodiazepine receptor agonist diazepam is a widely prescribed anxiolytic drug. Using the hole-board test, we had previously reported that diazepam exhibited anxiolytic-like effects (Matsumoto et al., 2021). Therefore, diazepam showed improvement in anxiety-like behavior in the LPS-treated mice.

It was reported that 92.7% of Japanese family physicians have prescribed Kampo medicine (Takayama et al., 2020). Kampo medicine can treat a wide variety of conditions from mental disorders to physical weakness. Kampo medicine, including crude drugs of saiko such as hochuekkito (HET, Bu Zhong Yi Qi Tang in Chinese, Bo jung ik gi tang in Korea), shigyakusan, shosaikoto, and yokukansan (YKS, Yi Gan San in Chinese, Ukgansan in Korea), has been frequently prescribed for the treatment of a wide variety of conditions from mental disorders to physical weakness. Especially, HET was developed considering its anti-stress effects related to an extreme situation in ancient China, but it continues to be useful for dealing with the stress of fear and its subsequent depressive condition (Koshikawa et al., 1998). In recent years, it has become clear that chronic environmental stress induces neural inflammation together with depression and anxiety (Nie et al., 2018). Previous studies have reported that HET prevents systemic inflammation in patients with chronic obstructive pulmonary disease (Tatsumi et al., 2009). Furthermore, HET has been shown to attenuate LPSinduced inflammation in a mouse model of lung emphysema (Tatsumi et al., 2009; Isago et al., 2021). It improves cachexia by inhibiting cytokine secretion in cancer-bearing mice (Yae et al., 2012). Therefore, we speculated that this drug may improve inflammatory reactions and inflammation-induced psychotic disorders. The effect of HET use in psychiatric disorders has not been investigated previously. In this study, we aimed to investigate the anxiolytic effect of HET on anxiety-like behavior in LPS-treated mice using the light-dark test and hole-board test. In addition, we assessed the effect of HET on IL-6 expression in LPS-treated mice and LPS-exposed human and mouse cell lines.

# Materials and methods

### Animals

This study was conducted in accordance with the recommendations of the Guide for Animal Experiments of the Advanced Science Research Center, Okayama University. The animal study protocol was approved by the Animal Care Use Committee of the Advanced Science Research Center, Okayama University (OKU-2020565). A total of 234 male Institute of Cancer Research (ICR) mice weighing 29–35 g were purchased from Charles River Laboratories (Yokohama, Japan). The mice were housed in an air-conditioned room  $(23 \pm 1^{\circ}C)$  with approximately 60% humidity) in groups of five per cage under a constant light-dark cycle (lights on from 08:00–20:00) and fed standard laboratory food and tap water.

### Drugs

LPS (from *Escherichia coli* O127:B8; Sigma-Aldrich, St. Louis, MO, United States) was dissolved in saline solution and administered by intraperitoneal (ip) injection at a dose of 1 ml/kg. Control mice were administered the vehicle. HET (Lot No. 20160041010) was provided by Tsumura & Co. (Tokyo, Japan). HET was used in the form of an extract powder made of the following raw materials: 4.0 parts Japanese Pharmacopoeia (JP) *Astragalus* root [*Astragalus membranaceus* Bunge, or *Astragalus mongholicus* Bunge (*Leguminosae*), radix], 4.0 parts JP Atractylodes lancea rhizome [*Atractylodes lancea* De Candolle, or *Atractylodes schinensis* Koidzumi (Asteraceae), hizome], 4.0 parts JP Ginseng [*Panax ginseng* C. A. Meyer (*Panax schinseng Nees*)

(Araliaceae), radix], 3.0 parts JP Japanese angelica root [Angelica acutiloba Kitagawa, or Angelica acutiloba Kitagawa var. sugiyamae Hikino (Umbelliferae), radix], 2.0 parts JP Bupleurum root [Bupleurum falcatum Linné (Umbelliferae), radix], 2.0 parts JP Jujube [Ziziphus jujuba Miller var. inermis Rehder (Rhamnaceae), fructus], 2.0 parts JP Citrus unshiu peel [Citrus unshiu Marcowicz, or Citrus reticulata Blanco (Rutaceae), pericarpium], 1.5 parts JP Glycyrrhiza [Glycyrrhiza uralensis Fischer, or Glycyrrhiza glabra Linné (Leguminosae), radix], 1.0 parts JP Cimicifuga rhizome [Cimicifuga simplex Turczaninow, Cimicifuga dahurica Maximowicz, Cimicifuga foetida Linné, or Cimicifuga heracleifolia Komarov (Ranunculaceae), hizome], and 0.5 parts JP ginger [Zingiber officinale Roscoe (Zingiberaceae), hizome]. The plants were identified by their external morphology and marker compounds as per the Japanese pharmacopeia and company standards. The extract quality was standardized based on good manufacturing practices, as defined by the Ministry of Health, Labour, and Welfare of Japan. The 10 herbs were boiled in purified water at 95°C for 1 h. The liquid extract solution was filtered from the non-soluble waste and reduced to a concentrate. The concentrate was spray-dried to produce the extract powder. А three-dimensional high-performance liquid chromatogram of HET provided by Tsumura & Co. is presented in Supplementary Figure S1. The HET powder was dissolved in distilled water and doses were set based on a previous report (Tohda and Mingmalairak 2013; Cai and Yang 2019; Kitamura et al., 2019). Glycyrrhizin (Tokyo Chemical Industry CO., LTD, Tokyo, Japan) was suspended in water in vivo and doses were set based on a previous report (Song et al., 2013).

### In vivo experimental schedule

We assessed the preventive effect of the repeated administration of HET and glycyrrhizin on the LPS-induced anxiety-like behaviors in mice using the hole-board test and light-dark test. HET (0.1–1.0 g/kg) and glycyrrhizin (10–30 mg/kg) was administered orally (po) once a day for 2 weeks until the day before the experiments. Diazepam (0.1–1.0 mg/kg) was administered intraperitoneally (ip) 30 min before the experiments. The animals were then intraperitoneally injected with LPS (300  $\mu$ g/kg) 1 h after the final HET and glycyrrhizin administration. The hole-board and light-dark box tests were performed 24 h after the LPS injection. Serum samples from mice were obtained 2, 5, and 24 h after the injection. The experiments were conducted between 10:00 and 16:00.

### Hole-board test

The hole-board test apparatus consisted of a gray box  $(50 \times 50 \times 50 \text{ cm})$  with 16  $(4 \times 4)$  equidistant holes 3 cm in diameter on the floor. The number of head dips registered in a 10 min session was recorded by an observer blinded to the experimental treatment. In addition, the locomotor activity of the mice was recorded by an

overhead charged-coupled device camera using LimeLight video tracking (ActiMetrics, Wilmette, IL, United States).

### Light-dark test

The light-dark box consisted of a light zone  $(20 \times 20 \times 25 \text{ cm})$ and a dark zone  $(20 \times 20 \times 25 \text{ cm})$  with black walls and floor), separated by a partition with a single opening  $(5 \times 8 \text{ cm})$  to allow the mice to pass from one zone to the other. Illumination in the light zone was 500 lx, while that in the dark zone was prevented by covering with a lid. A mouse was placed in the center of the light zone at the beginning of the test and the total time it spent in the light zone was recorded for 10 min.

### Cell lines

The human acute myeloid leukemia cell line THP-1 was obtained from the RIKEN BioResource Center (Ibaraki, Japan), and the mouse macrophage cell line RAW264.7, was obtained from the European Collection of Authenticated Cell Cultures (Salisbury, United Kingdom). THP-1 cells were maintained in RPMI1640 medium (Thermo Fisher Scientific, MA, United States) supplemented with 10% fetal bovine serum (FBS) and 10 mg/ml of 1% (v/v) penicillin-streptomycin (Sigma-Aldrich, MO, United States). RAW264.7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific, MA, United States) supplemented with 10% FBS and 10 mg/ml of 1% (v/v) penicillin-streptomycin.

### In vitro experimental schedule

THP-1 cells were seeded at a density of  $2 \times 10^4$  cells/cm<sup>2</sup> into 24 well plates. Phorbol 12-myristate 13-acetate (PMA) at a concentration of 200 nM was added to induce differentiation of the cells into macrophages and incubated for 24 h at 37°C in humidified air supplemented with 5% CO<sub>2</sub>. The cells were then exposed to LPS (1.0 µg/ml) and HET (50, 100, and 300 ng/ml) and cultured for another 24 h. The culture supernatant was collected and the concentration of IL-6 secreted in it was measured. Likewise, the RAW264.7 cells were seeded at a density of  $5 \times 10^3$  cells/cm<sup>2</sup> into 24 well plates and incubated for 24 h. The cells were exposed to LPS (1.0 µg/ml) and HET (50, 100, and 300 ng/ml) for 24 h. The concentration of IL-6 in the culture supernatant was determined.

# Measurement of IL-6 concentrations in serum and culture medium

IL-6 concentrations in serum and culture medium were determined by enzyme-linked immunosorbent assay (ELISA)



using the mouse IL-6 antibody pair or human IL-6 antibody pair (Thermo Fisher Scientific Inc., Cleveland, OH, United States) according to the manufacturer's instructions. The assay range for human IL-6 was 2–200 pg/ml. The assay range for mouse IL-6 was 4–500 pg/ml.

## Statistics

Values were expressed as mean  $\pm$  standard error of mean (SEM). The data were analyzed by Student's t-test or one way and two-way analysis of variance (ANOVA), followed by Dunnett's

test or Tukey-Kramer test (StatView 5.0; Abacus Concepts, Berkely, CA, United States) to determine differences among the groups. p < 0.05 was considered as statistically significant.

# Results

# Effect of HET on LPS-induced anxiety-like behaviors in the light-dark test

In the light-dark test, the light-dark box represents an anxiogenic challenge that tests the conflict between the desire to explore new environments and aversion to brightly lit zone. Diazepam significantly increased the time spent in the light [F (3, 20) = 10.02, p < 0.01] (Figure 1A). Additionally, HET also significantly increased the time spent in light [F (3, 26) = 3.81, p < 0.05] (Figure 1B). In contrast, LPS-treatment significantly reduced the amount of time the mice spent in light. In LPS-treated mice, HET significantly increased the time spent in light [LPS: F (1, 13) = 2.89, p = 0.11; HET: F (1, 13) = 3.49, p = 0.08; LPS×HET: F (1, 13) = 2.75, p = 0.12] (Figure 3A).

# Effect of HET on LPS-induced anxiety-like behavior in the hole-board test

The hole-board test is an anxiogenic challenge to assess emotionality and anxiety responses to stress in animals. Diazepam significantly increased the number of head dips in naïve mice [F (3, 20) = 7.33, p < 0.01] (Figure 2A). HET did not change the number of head dips in naïve mice [F (3, 22) = 1.06, p = 0.39] (Figure 2B). In contrast, LPS-treated mice showed significantly fewer head dips, and HET significantly reversed the number of head dips in LPS-treated mice [LPS: F (1, 15) = 17.67, p < 0.01; HET: F (1, 13) = 10.28, p < 0.01; LPS×HET: F (1, 13) = 1.07, p = 0.32] (Figure 3B). None of the drugs showed a significant effect on locomotor activity in mice at 24 h after LPS treatment (data not shown).

### Effect of glycyrrhizin on LPS-induced anxiety-like behavior in the hole-board test and the light-dark test

Glycyrrhizin (30 mg/kg) significantly increased the number of head dips and the time spent in light in naïve mice [Holeboard test: F (3, 20) = 3.89, p < 0.05; Light-dark test: F (3, 20) = 2.14, p = 0.13] (Table 1). In contrast, glycyrrhizin (30 mg/kg) significantly reversed the number of head dips t and the time spent in the light in LPS-treated mice [Hole board test: LPS: F (1, 11) = 8.21, p < 0.05; HET: F (1, 11) = 3.74, p = 0.08; LPS×HET: F (1, 11) = 0.11, p = 0.75]; Light-dark test: LPS: F (1, 11) = 35.73, p <



0.01; HET: F (1, 11) = 10.07, p < 0.01; LPS×HET: F (1, 11) = 0.12, p = 0.73] (Figure 4).

### Effect of HET the serum IL-6 levels of LPSinduced mice

LPS-treatment caused a significant increase in IL-6 serum concentrations after 2 and 5 h (Figure 5). In all LPS-treated mice, the serum level of IL-6 was below the minimum limit of detection after 24 h. HET did not affect LPS-induced increase in serum IL-6 after 2 h. However, it significantly reduced LPS-induced serum IL-6 increase after 5 h compared to control (*t*-value = 2.964, p < 0.01).



# Effect of HET on LPS-induced IL-6 secretion by macrophages

THP-1 and RAW264.7 cells were used to investigate the effect of HET on LPS-induced IL-6 secretion by macrophages. Exposure of HET at concentrations of 0, 10, 50, 100, and 300 µg/ml did not affect the proliferation of THP-1 cells or RAW264.7 cells (data not shown). LPS exposure at a concentration of 1.0 µg/ml significantly increased IL-6 secretion by THP-1 and RAW264.7 cells. HET significantly suppressed LPS-induced increased IL-6 secretion by RAW264.7 (Figure 6A) [F (3, 12) = 10.325, p < 0.05] and THP-1 (Figure 6B) [F (3, 9) = 71.260, p < 0.01] cells.

TABLE 1 Results of the light-dark test and the hole-board test. Effect of glycyrrhizin on time spent in the light zone and the number of head dips in control mice, mice administered glycyrrhizin for 2 weeks. Data are shown as mean  $\pm$  standard error of mean (SEM); n = 6 per group. \*: p < 0.05 (vs. control).

_	$152.0 \pm 18.1$
10	$186.0 \pm 14.7$
30	250.8 ± 32.3*
50	157.8 ± 22.8
Dose (mg/g)	Time spent in light zone (sec)
_	$170.8 \pm 16.8$
10	181.7 ± 23.8
30	$247.0 \pm 23.2^*$
50	184.5 ± 29.1
	30 50 <b>Dose (mg/g)</b>  10 30

# Discussion

Several studies have shown that LPS induces anxiety-like behavior in mice (Choubey et al., 2019; Jiang et al., 2019; Sabedra Sousa et al., 2019). An increase in inflammatory markers may induce anxiety-like behavior in animal models (Sulakhiya et al., 2016). We previously reported that LPS treatment increased the production of the pro-inflammatory cytokine IL-6 in the serum, and IL-6 and TNF- $\alpha$  in the hippocampus (Kitamura et al., 2019). In this study, HET was shown to ameliorate anxiety-like behavior (through the light-dark test and hole-board test) and decrease IL-6 levels in LPS-treated mice. Peripheral IL-6 plays an important role in depression-like phenotype after social defeat stress (Yang et al., 2015). Additionally, elevated IL-6 levels in serum are strongly correlated with depression and anxiety symptoms (Hodes et al., 2016). Several reports have shown that blockade of IL-6 signaling (for example, through anti-IL-6 receptor antibody) can be a potential therapeutic strategy for psychiatric disorders (Zhang et al., 2017; Zhou et al., 2017). Therefore, we can assume that IL-6 plays a role in anxiety and depression.

In this study, we used the light-dark test and the hole-board test. These behavioral tests have been previously used to assess anxiogenic and anxiolytic states. A single administration of diazepam, a typical anxiolytic drug, significantly increased time spent in the light compared with the vehicle group. This finding confirmed the anxiolytic-like action of diazepam reported previously (Bourin and Hascoët 2003). According to previous studies, the number of head-dips was also significantly increased by treatment with diazepam in the hole-board test (Takeda et al., 1998). Here, we observed the anxiolytic effect of



diazepam with the light-dark test and hole board test. Therefore, these procedures were effective for the evaluation of anxiety-like behaviors in this study.

HET is known to reduce rhinovirus-induced secretion of IL-6 from human tracheal epithelial cells *in vitro* (Yamaya et al., 2007). Treatment with HET has been shown to decrease serum



IL-6 in patients with chronic obstructive pulmonary disease (Tatsumi et al., 2009). Therefore, we can safely assume that HET modulates IL-2 levels. The production of IL-6 in the blood is carried out by immunocompetent cells, such as monocytes and macrophages (Horii et al., 1988). Therefore, we focused on the effects of HET on macrophages. We found that HET decreased LPS-induced IL-6 expression and secretion in human and mouse macrophages, similar to the findings with the mouse models used in this study. These results are consistent with those of a previous study (Yae et al., 2012). Furthermore, HET significantly reduced LPS-induced serum IL-6 levels in mice after 5 h. Therefore, we postulate that HET improves LPS-induced anxiety-like behavior by modulating serum IL-6 levels at an early stage of inflammation.

Regarding the active components responsible for the effects of HET, several major chemical components have been previously identified (Kao et al., 2001; Yamaya et al., 2007). In this study, we especially focused on glycyrrhizin (Lai et al., 2020). We have shown that glycyrrhizin improved LPS-induced anxiety-like behavior. These results suggest that glycyrrhizin could be one of the main constituents of HET that contributes to anxiolytic-like actions under inflammatory conditions. Moreover, HET is composed of ten crude drugs. Among them, ginseng is reported to prevent psychosocial stressinduced psychiatric disorders (Ben-Azu et al., 2020). Ginseng's main components suppressed immobilization stress and immobilization stress-induced serum levels of IL-6. The anxiolytic effects were shown to occur via the yaminobutyrate<sub>A</sub> (GABA<sub>A</sub>) receptor and serotonergic receptor. Therefore, several crude drugs composed HET may contribute to the anxiolytic-like effects observed in this study.

Toll-like receptors (TLRs) are pattern recognition receptors localized on the cell surface of macrophages and other innate immune cells and play an important role in host defense responses (Fitzgerald and Kagan 2020). LPS, a major component



stimulated RAW264.7 (A) and THP-1 (B) macrophages incubated in the presence or absence of various concentrations (50–300  $\mu$ g/ ml) of HET. Data are shown as mean  $\pm$  SEM; n = 4 per group. <sup>II</sup>: p < 0.01 (vs. LPS alone).

of the extracellular membranes of gram-negative bacteria, is one of the best-studied immunostimulatory exogenous ligands for TLR4. LPS can induce systemic and local tissue inflammation (Lu et al., 2008), and TLRs are an integral part of inflammatory responses. LPS activates macrophages and microglia by selectively stimulating TLR4 and triggering the nuclear factor-kappa B (NF- $\kappa$ B) and mitogen-activated protein kinase pathways (Fu et al., 2013), resulting in the excessive production of pro-inflammatory cytokines (Kim et al., 2012; Wang et al., 2014). It was reported that HET significantly suppressed the increase in LPS-induced TNF- $\alpha$ , a pro-inflammatory cytokine, in human macrophage cell lines, including that used in our study (Isago et al., 2021). HET may also ameliorate inflammation-induced anxiety by inhibiting TLR4 signaling. Moreover, glycyrrhizin is a natural inhibitor of high mobility group box 1 (HMGB1) which has exerted neuroprotective effect against several HMGB1 mediated pathological condition (Mollica et al., 2007). When released into the extracellular settings, HMGB1 exerts biological activity mainly via interaction with its prominent binding partner toll-like receptor-4 (TLR4) and receptor for advanced glycation end products. Thus, it is possible that HET suppress the inflammatory responses included HMGB1/TLR-4/NF- $\kappa$ B signaling pathway. However, as the NF- $\kappa$ B, HMGB1 and MAPK pathways, which are related signals of TLR4, were not examined in this study, further studies are needed to validate this hypothesis.

In conclusion, we demonstrated that HET ameliorated anxiogenic-like behavior under inflammatory conditions induced by LPS using two different behavioral models. Additionally, it was revealed that glycyrrhizin, one of the chemical constituents of HET, suppressed LPS-induced anxietylike behavior. We also showed that HET decreased IL-6 expression in LPS-induced mice and LPS-exposed macrophages. In conclusion, our study demonstrated that HET inhibits cytokine release, suggesting that the effect of HET on inflammation-induced anxiety-like behavior involves an anti-inflammatory action through IL-6 suppression in the early stages of inflammation.

### Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

# **Ethics statement**

The animal study was reviewed and approved by The Animal Care Use Committee of the Advanced Science Research Center, Okayama University.

# Author contributions

SU: Experimentation, Data curation, Formal analysis, and Writing-original draft. YW: Experimentation, Data curation, and Formal analysis. MN: Experimentation, Formal analysis. DM:

# References

Ben-Azu, B., Emokpae, O., Ajayi, A. M., Jarikre, T. A., Orhode, V., Aderibigbe, A. O., et al. (2020). Repeated psychosocial stress causes glutamic acid decarboxylase isoform-67, oxidative-nox-2 changes and neuroinflammation in mice: Prevention by treatment with a neuroactive flavonoid, morin. *Brain Res.* 1744, 146917. doi:10.1016/j.brainres.2020.146917

Experimentation, Formal analysis. KH: Experimentation, Formal analysis. SS: Experimentation, Formal analysis. NI: Experimentation, Formal analysis. SE: Formal analysis, Data curation. MK: Formal analysis, Data curation. YK: Funding acquisition, Supervision, Intellectual support, and Manuscript revision. TS: Funding acquisition, Supervision, and Intellectual support. All authors read and approved the final version of the manuscript.

# Funding

This study received funding from Tsumura Co. (Tokyo, Japan). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

# Acknowledgments

The authors are grateful to Tsumura & Co. (Tokyo, Japan) for providing HET.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar. 2022.890048/full#supplementary-material

Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., et al. (2011). Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. *Neurosci. Biobehav. Rev.* 35, 804–817. doi:10.1016/j.neubiorev.2010.10.001

Bourin, M., and Hascoët, M. (2003). The mouse light/dark box test. *Eur. J. Pharmacol.* 463, 55–65. doi:10.1016/s0014-2999(03)01274-3

Cai, M., and Yang, E. J. (2019). Hochu-ekki-to improves motor function in an amyotrophic lateral sclerosis animal model. *Nutrients* 11, 2644. doi:10.3390/nu11112644

Choubey, P., Kwatra, M., Pandey, S. N., Kumar, D., Dwivedi, D. K., Rajput, P., et al. (2019). Ameliorative effect of fisetin against lipopolysaccharide and restraint stress-induced behavioral deficits via modulation of NF- $\kappa$ B and Ido-1. *Psychopharmacology* 236, 741–752. doi:10.1007/s00213-018-5105-3

Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., et al. (2010). A meta-analysis of cytokines in major depression. *Biol. Psychiatry.* 67, 446–457. doi:10.1016/j.biopsych.2009.09.033

Fitzgerald, K. A., and Kagan, J. C. (2020). Toll-like receptors and the control of immunity. *Cell* 180, 1044–1066. doi:10.1016/j.cell.2020.02.041

Fu, Y., Liu, B., Zhang, N., Liu, Z., Liang, D., Li, F., et al. (2013). Magnolol inhibits lipopolysaccharide-induced inflammatory response by interfering with TLR4 mediated NF-κB and MAPKs signaling pathways. *J. Ethnopharmacol.* 145, 193–199. doi:10.1016/j.jep.2012.10.051

Godbout, J. P., Chen, J., Abraham, J., Richwine, A. F., Berg, B. M., Kelley, K. W., et al. (2005). Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. *FASEB J.* 19, 1329–1331. doi:10.1096/fj.05-3776fje

Goldsmith, D. R., Rapaport, M. H., and Miller, B. J. (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. *Mol. Psychiatry.* 21, 1696–1709. doi:10.1038/mp.2016.3

Hodes, G. E., Ménard, C., and Russo, S. J. (2016). Integrating interleukin-6 into depression diagnosis and treatment. *Neurobiol. Stress* 4, 15–22. doi:10.1016/j.ynstr. 2016.03.003

Horii, Y., Muraguchi, A., Suematsu, S., Matsuda, T., Yoshizaki, K., Hirano, T., et al. (1988). Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophagedependent synthesis of BSF-2/IL-6 by T cells. *J. Immunol.* 141, 1529–1535.

Huang, Y., Henry, C. J., Dantzer, R., Johnson, R. W., and Godbout, J. P. (2008). Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. *Neurobiol. Aging.* 29, 1744–1753. doi:10.1016/j.neurobiolaging.2007.04.012

Isago, H., Mitani, A., Kohno, S., Nagoshi, S., Ishimori, T., Saito, M., et al. (2021). The Japanese herbal (Kampo) medicine Hochuekkito attenuates lung inflammation in lung emphysema. *Biol. Pharm. Bull.* 44, 39–45. doi:10.1248/bpb.b20-00556

Jangra, A., Lukhi, M. M., Sulakhiya, K., Baruah, C. C., and Lahkar, M. (2014). Protective effect of mangiferin against lipopolysaccharide-induced depressive and anxiety-like behaviour in mice. *Eur. J. Pharmacol.* 740, 337–345. doi:10.1016/j. eiphar.2014.07.031

Jiang, X., Wang, G., Lin, Q., Tang, Z., Yan, Q., Yu, X., et al. (2019). Fucoxanthin prevents lipopolysaccharide-induced depressive-like behavior in mice via AMPK-NF- $\kappa$ B pathway. *Metab. Brain Dis.* 34, 431–442. doi:10.1007/s11011-018-0368-2

Kao, S. T., Yeh, C. C., Hsieh, C. C., Yang, M. D., Lee, M. R., Liu, H. S., et al. (2001). The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. *Life Sci.* 69, 1485–1496. doi:10. 1016/s0024-3205(01)01226-7

Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., Jones, P. B., et al. (2015). Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. *Lancet. Psychiatry* 2, 258–270. doi:10.1016/S2215-0366(14)00122-9

Kim, H. S., Kim, Y. J., Lee, H. K., Ryu, H. S., Kim, J. S., Yoon, M. J., et al. (2012). Activation of macrophages by polysaccharide isolated from Paecilomyces cicadae through toll-like receptor 4. *Food Chem. Toxicol.* 50, 3190–3197. doi:10.1016/j.fct. 2012.05.051

Kitamura, Y., Hongo, S., Yamashita, Y., Yagi, S., Otsuki, K., Miki, A., et al. (2019). Influence of lipopolysaccharide on diazepam-modified loss of righting reflex duration by pentobarbital treatment in mice. *Eur. J. Pharmacol.* 842, 231–238. doi:10.1016/j.ejphar.2018.10.049

Koshikawa, N., Imai, T., Takahashi, I., Yamauchi, M., Sawada, S., and Kansaku, A. (1998). Effects of Hochu-ekki-to, Yoku-kan-san and Saiko-ka-ryukotsu-borei-to on behavioral despair and acetic acid-induced writhing in mice. *Methods Find. Exp. Clin. Pharmacol.* 20, 47–51. doi:10.1358/mf.1998.20.1.485631

Lai, S., Shi, L., Jiang, Z., and Lin, Z. (2020). Glycyrrhizin treatment ameliorates post-traumatic stress disorder-like behaviours and restores circadian oscillation of intracranial serotonin. *Clin. Exp. Pharmacol. Physiol.* 47, 95–101. doi:10.1111/1440-1681.13173

Leonard, B., and Maes, M. (2012). Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and

their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci. Biobehav. Rev.* 36, 764–785. doi:10.1016/j.neubiorev.2011. 12.005

Lu, Y. C., Yeh, W. C., and Ohashi, P. S. (2008). LPS/TLR4 signal transduction pathway. *Cytokine* 42, 145–151. doi:10.1016/j.cyto.2008.01.006

Månsson, K. N. T., Lasselin, J., Karshikoff, B., Axelsson, J., Engler, H., Schedlowski, M., et al. (2022). Anterior insula morphology and vulnerability to psychopathology-related symptoms in response to acute inflammation. *Brain Behav. Immun.* 99, 9–16. doi:10.1016/j.bbi.2021.09.007

Matsumoto, D., Ushio, S., Wada, Y., Noda, Y., Esumi, S., Izushi, Y., et al. (2021). Bumetanide prevents diazepam-modified anxiety-like behavior in lipopolysaccharide-treated mice. *Eur. J. Pharmacol.* 904, 174195. doi:10.1016/j. ejphar.2021.174195

Mollica, L., De Marchis, F., Spitaleri, A., Dallacosta, C., Pennacchini, D., Zamai, M., et al. (2007). Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. *Chem. Biol.* 14, 431–441. doi:10.1016/j.chembiol. 2007.03.007

Nie, X., Kitaoka, S., Tanaka, K., Segi-Nishida, E., Imoto, Y., Ogawa, A., et al. (2018). The innate immune receptors TLR2/4 mediate repeated social defeat stressinduced social avoidance through prefrontal microglial activation. *Neuron* 99, 464–479. e7. doi:10.1016/j.neuron.2018.06.035

Sabedra Sousa, F. S., Birmann, P. T., Bampi, S. R., Fronza, M. G., Balaguez, R., Alves, D., et al. (2019). Lipopolysaccharide-induced depressive-like, anxiogenic-like and hyperalgesic behavior is attenuated by acute administration of alpha-(phenylselanyl) acetophenone in mice. *Neuropharmacology* 146, 128–137. doi:10. 1016/j.neuropharm.2018.11.028

Song, J. H., Lee, J. W., Shim, B., Lee, C. Y., Choi, S., Kang, C., et al. (2013). Glycyrrhizin alleviates neuroinflammation and memory deficit induced by systemic lipopolysaccharide treatment in mice. *Molecules* 18, 15788–15803. doi:10.3390/ molecules181215788

Sulakhiya, K., Keshavlal, G. P., Bezbaruah, B. B., Dwivedi, S., Gurjar, S. S., Munde, N., et al. (2016). Lipopolysaccharide induced anxiety- and depressive-like behaviour in mice are prevented by chronic pre-treatment of esculetin. *Neurosci. Lett.* 611, 106–111. doi:10.1016/j.neulet.2015.11.031

Takayama, S., Akaishi, T., Nozaki, H., Suzuki, S., Arita, R., Saito, N., et al. (2020). Characteristics and course of patients treated with Kampo medicine in the department of general medicine. *J. Gen. Fam. Med.* 21, 48–55. doi:10.1002/jgf2.294

Takeda, H., Tsuji, M., and Matsumiya, T. (1998). Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. *Eur. J. Pharmacol.* 350, 21–29. doi:10.1016/S0014-2999(98)00223-4

Tatsumi, K., Shinozuka, N., Nakayama, K., Sekiya, N., Kuriyama, T., Fukuchi, Y., et al. (2009). Hochuekkito improves systemic inflammation and nutritional status in elderly patients with chronic obstructive pulmonary disease. *J. Am. Geriatr. Soc.* 57, 169–170. doi:10.1111/j.1532-5415.2009.02034.x

Tohda, M., and Mingmalairak, S. (2013). Evidence of antidepressive effects of aWakanyaku, Hochuekkito, in depression model mice with learned-helplessness behavior. *Evid. Based. Complement. Altern. Med.* 2013, 319073. doi:10.1155/2013/319073

Wang, X., Hu, D., Zhang, L., Lian, G., Zhao, S., Wang, C., et al. (2014). Gomisin A inhibits lipopolysaccharide-induced inflammatory responses in N9 microglia via blocking the NF-κB/MAPKs pathway. *Food Chem. Toxicol.* 63, 119–127. doi:10.1016/j.fct.2013.10.048

Yae, S., Takahashi, F., Yae, T., Yamaguchi, T., Tsukada, R., Koike, K., et al. (2012). Hochuekkito (TJ-41), a Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. *Evid. Based. Complement. Altern. Med.* 2012, 976926. doi:10.1155/2012/976926

Yamaya, M., Sasaki, T., Yasuda, H., Inoue, D., Suzuki, T., Asada, M., et al. (2007). Hochu-ekki-to inhibits rhinovirus infection in human tracheal epithelial cells. *Br. J. Pharmacol.* 150, 702–710. doi:10.1038/sj.bjp.0707135

Yan, J., Fu, Q., Cheng, L., Zhai, M., Wu, W., Huang, L., et al. (2014). Inflammatory response in Parkinson's disease (Review).. *Mol. Med. Rep.* 10, 2223–2233. doi:10. 3892/mmr.2014.2563

Yang, C., Shirayama, Y., Zhang, J. C., Ren, Q., and Hashimoto, K. (2015). Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable electric stress. *Acta Neuropsychiatr.* 27, 312–316. doi:10.1017/ neu.2015.36

Zhang, J. C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., et al. (2017). Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: A possible role of gut-microbiota-brain axis. *Transl. Psychiatry*. 7, e1138. doi:10.1038/tp.2017.112

Zhou, A. J., Lee, Y., Salvadore, G., Hsu, B., Fonseka, T. M., Kennedy, S. H., et al. (2017). Sirukumab: A potential treatment for mood disorders? *Adv. Ther.* 34, 78–90. doi:10.1007/s12325-016-0455-x